Prevalence Of Molecular Markers Linked To Sulfadoxinepyrimethamine Resistance In Plasmodium Falciparum At Pawe North Western Ethiopia

In 1999, following high treatment failure rates of chloroquine, the Ethiopian Ministry of Health gave directives for the use of Sulfadoxine/pyrimethamine (SP) as first line drug for the treatment of uncomplicated falciparum malaria. In 2004, this decision was altered due to high treatement failure of SP and Arthemether-Lumfantrine (Coartem®rnPfdhfr; Pfdhps; dot blot hybridization; Ethiopia ) was introduced. The study investigated the impact of withdrawal of SP on the change in frequency of SP resistance-related haplotypes in Pfdhfr (codons 51, 59 and 108) and Pfdhps (codons 437 and 540) genes by PCR based dot blot hybridization. Plasmodium falciparum positive blood samples were collected from a total of 159 patients during two cross sectional surveys in 2005 (N=80) and 2007/08 (N=79) from Pawe, North Western Ethiopia. It was determined that the frequency of SP resistance associated triple mutant Pfdhfr haplotype decreased significantly from 50.79% to 15.87% (P0.05) both of which showed that the prevalence of mutatnt alleles that cofer drug resistance are decreasing in the absence of drug pressure. The combined Pfdhfr/Pfdhps quintuple mutant haplotype that has been previously recognized to be the most important determinant of SP resistance was significantly decreased from 40.68% to 13.56% (P

Get Full Work

Report copyright infringement or plagiarism